Abstract: From PBMCs of patients infected with H1N1pdm, three human monoclonal antibodies have been obtained which are capable of binding to an epitope present at residues 40 to 58 in an HA2 region of a hemagglutinin protein derived from H1N1pdm. Further, these antibodies have been found to also have a neutralization activity against subtype H1 and subtype H5 of group 1 influenza A viruses. On the other hand, the three antibodies have also been found to exhibit neither a binding ability nor a neutralization activity against subtype H2 which belongs to the group 1, but in the HA2 region derived from H1N1pdm of which the amino acid at residue 45 is substituted with phenylalanine and the amino acid at residue 47 is substituted with glycine.

Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.

Abstract: The present invention provides fully human antibodies that bind to either toxin A or toxin B of Clostridium difficile, or to both toxin A and toxin B, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for neutralizing the toxins from C. difficile, thus providing a means of treating the disease and symptoms associated with a C. difficile infection, including the treatment of diarrhea, or pseudomembranous colitis caused by C. difficile. The antibodies may also prevent the severity and/or duration of the primary disease, or may prevent the number, duration, and/or the severity of recurrences, or relapses of the disease attributed to the presence of C. difficile. The antibodies of the invention may also be useful for diagnosis of an infection by C. difficile.

Abstract: The invention provides antibodies against the A2 domain of tenascin-C and methods of using the same.

Abstract: A glycan having the structure gal?1-3GLcNac?1-3Gal?1-4(Fuc?1-3)GlcNAc (LecLex) which is attached to a lipid or protein backbone, and isolated binding members capable of binding thereto.

Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of such modulators to treat hyperproliferative disorders are provided.

Abstract: The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.

Abstract: CREB3L1 is a biomarker for identifying cancer cells sensitive to doxorubicin (daunomycin).

Abstract: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.

Abstract: The methods and uses described herein relate to the treatment of age-related conditions, e.g. by administering an agent that inhibits the interaction of GDF11 and follistatin. In some embodiments, the agent can bind to an epitope of GDF11 as described herein.

Abstract: The present disclosure relates to TSLP binding proteins, such as anti-TSLP single variable domains, polynucleotides encoding such TSLP binding proteins, pharmaceutical compositions and kits comprising said TSLP binding proteins and methods of manufacture. The present invention also concerns the use of such TSLP binding proteins in the treatment of diseases associated TSLP signaling, such as asthma.

Abstract: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and thera

Abstract: The present invention relates to anti-IL-3 antibodies or IL-3 binding fragments thereof for use in the treatment of an autoimmune disease selected from the group consisting of systemic lupus erythematosus and multiple sclerosis, and to pharmaceutical compositions comprising such an antibody or antibody fragment.

Abstract: Provided herein is an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80), and the antibody inhibits the binding of human IL-12 to human IL-12R?2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12R?1.

Abstract: Antibodies that specifically bind TEM8 protein, conjugates thereof, and their use, are disclosed herein. In some examples the conjugates and antibodies are useful for methods of detecting and treating pathogenic angiogenesis. In other examples the conjugates and antibodies are useful for methods of detecting and treating cancer. In additional examples, the conjugates and antibodies are useful for methods of decreasing binding of Anthrax protective antigen to a cell.

Abstract: The present invention is directed to compositions of matter useful for the treatment of cancer in mammals and to methods of using those compositions of matter for the same. Antibodies specific for podocalyxin designated Ab1 and 3G2 are disclosed, as is the use of said antibodies for the inhibition of growth of a tumor that expresses podocalyxin, and the use of said antibodies for targeting tumour endothelial cells that express podocalyxin.

Abstract: The present invention relates to a method for generating immunoglobulin sequences against cell-associated antigens, more particularly, antigens that are membrane-anchored. The invention also provides immunoglobulin sequences obtainable by the method of the invention. Specifically, the present invention relates to the generation of immunoglobulin sequences by use of DNA vaccination. More specifically, the present invention relates to generation of immunoglobulin sequences in camelids, preferably directed against cell-associated antigens, in particular antigens with multiple transmembrane spanning domains, including GPCRs and ion channels, by DNA vaccination. Furthermore, the present invention relates to said immunoglobulin sequences against cell-associated antigens, more particularly, antigens that are membrane-anchored, such as e.g. GPCRs and ion channels, more preferably ion channels.

Abstract: The present disclosure provides binding-triggered transcriptional switch polypeptides, nucleic acids comprising nucleotide sequences encoding the binding-triggered transcriptional switch polypeptides, and host cells genetically modified with the nucleic acids. The present disclosure also provides chimeric Notch receptor polypeptides, nucleic acids comprising nucleotide sequences encoding the chimeric Notch receptor polypeptides, and host cells transduced and/or genetically modified with the nucleic acids. The present disclosure provides transgenic organisms comprising a nucleic acid encoding a binding triggered transcriptional switch polypeptide and/or a chimeric Notch receptor polypeptide of the present disclosure. Binding triggered transcriptional switch polypeptides and chimeric Notch receptor polypeptides of the present disclosure are useful in a variety of applications, which are also provided.

Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.

Abstract: The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of B7-H1.

Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.

Abstract: Provided are novel methods of reducing the serum levels of Fc-containing agents (e.g., antibodies and immunoadhesins) in a subject. These methods generally comprise administering to the subject an effective amount of an isolated FcRn-antagonist that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. The disclosed methods are particularly useful for treating antibody-mediated disorders (e.g. autoimmune diseases).

Abstract: The invention described herein relates to therapeutic dosing regimens and combinations thereof for use in enhancing the therapeutic efficacy of anti-CS1 antibodies in combination with one or more immunotherapeutic agents.

Abstract: The present invention provides a method for the selection of bispecific single chain antibodies comprising a first binding domain capable of binding to an epitope of CD3 and a second binding domain capable of binding to the extracellular domain cell surface antigens with a high molecular weight extracellular domain. Moreover, the invention provides bispecific single chain antibodies produced by the use of the method of the invention, nucleic acid molecules encoding these antibodies, vectors comprising such nucleic acid molecules and methods for the production of the antibodies. Furthermore, the invention provides pharmaceutical compositions comprising bispecific single chain antibodies of the invention, medical uses of the same and methods for the treatment of diseases comprising the administration of bispecific single chain antibodies of the invention.

Abstract: The present invention relates to antibodies that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.

Abstract: The technology described herein relates to antibodies and/or polypeptides which bind to MIC and inhibit MIC shedding. Methods of using such antibodies and/or polypeptides for the treatment of cancer are also described herein.

Abstract: The invention relates to APRIL-binding antibodies, which bind the same epitope of human APRIL as an antibody having an antigen binding site of hAPRIL.01A. The antibodies of the present invention comprise specific selections of framework sequences of the VH and VL domains and have unexpected features in comparison to hAPRIL.01A. The invention further relates to compositions comprising an antibody of the invention and to the medical and diagnostic uses of the antibodies and compositions.

Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.

Abstract: The present invention pertains to novel antibodies capable of binding to CD26, as well as to their use as a medicament. Moreover, the present invention provides antibodies for use in treating and/or preventing Graft-versus-Host Disease (GvHD), for use in treating Aplastic Anemia and/or for use in promoting engraftment after haematopoietic stem cell transplantation. Furthermore, the present invention provides pharmaceutical compositions comprising at least one antibody of the present invention, as well as provides a kit of parts.

Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.

Abstract: The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for Trop-2 (EGP-1) and at least one binding site for CD3. The bispecific antibodies are of use for inducing an immune response against a Trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate. The methods may comprising administering the bispecific antibody alone, or with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-?), and/or checkpoint inhibitor antibodies. The bispecific antibody is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of Trop-2+ cancer cells. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC.

Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.

Abstract: The invention relates to human neutralizing anti-KIT antibodies and uses thereof. More particularly, the invention relates to an antibody comprising a heavy chain variable region comprising SEQ ID NO: 2 in the H-CDR1 region, SEQ ID NO: 3 in the H-CDR2 region and SEQ ID NO: 4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO: 7 in the L-CDR2 region and SEQ ID NO: 8 in the L-CDR3 region. The invention also relates to an antibody comprising a heavy chain variable region comprising SEQ ID NO: 10 in the H-CDR1 region, SEQ ID NO: 11 in the H-CDR2 region and SEQ ID NO: 12 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 14 in the L-CDR1 region, SEQ ID NO: 15 in the L-CDR2 region and SEQ ID NO: 16 in the L-CDR3 region.

Abstract: In certain aspects, the present invention provides compositions and methods for increasing adiponectin in a patient in need thereof by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-activin A and/or B antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, and anti-BMP7 antibodies. Also provided are methods for ameliorating one or more undesired effects of anti-androgen therapy, including muscle loss, bone loss, increased adiposity, and/or increased insulin resistance. A variety of disorders may be treated by causing an increase in circulating adiponectin concentrations.

Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.

Abstract: The present invention relates to the use of tissue non-specific alkaline phosphatase (TNAP) as a marker for identifying and/or isolating adult multipotential cells. The present invention also relates to cell populations enriched by methods of the present invention and therapeutic uses of these cells.

Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives and fragments thereof as well as compositions and kits comprising them.

Abstract: The invention relates to the purification of bispecific antibodies carrying a different specificity for each binding site of the immunoglobulin molecule from a mixture of monospecific antibodies. The bispecific antibodies are composed of a single heavy chain and two different light chains, one containing a Kappa constant domain and the other a Lambda constant domain. This invention in particular relates to the isolation of these bispecific antibodies from mixtures that contain monospecific antibodies having two Kappa light chains or portions thereof and monospecific antibodies having two Lambda light chains or portions thereof. The invention also provides the methods of efficiently purifying these bispecific antibodies.

Abstract: A method for producing a polymer, which contains: bringing a monomer containing a vinyl bond into contact with a compressive fluid and melting or dissolving the monomer containing a vinyl bond, followed by carrying out addition polymerization of the monomer containing a vinyl bond in the presence of an initiator.

Abstract: A method of binding a detectable marker to a surface comprising the steps of exposing the surface to an electron beam to produce an electron beam-treated surface; applying a detectable marker to the electron beam-treated surface; and thereby producing a surface-bound detectable marker on the treated surface. The detectable marker can be any suitable marker such as an optical marker, a dye, a fluorophore, a biomolecule, a metal, or a rare earth element. Also provided is a composition including a detectable marker immobilized on a surface pre-treated with an electron beam.

Abstract: Process for modifying a polymer in the absence of elemental sulfur amounts larger than 0.5 phr, comprising the steps of a. mixing said polymer with a maleimide-functionalized mono-azide at a temperature in the range 80-250° C. to form a functionalised polymer, and b. thermally treating the functionalised polymer at a temperature in the range 50-270° C.

Abstract: An elastomeric composition and method incorporating a hydrocarbon polymer modifier with improved permanence. The composition comprises elastomer, filler and silane-functionalized hydrocarbon polymer modifier (Si-HPM) adapted to couple the Si-HPM to the elastomer, filler or both, wherein the Si-HPM comprises an interpolymer of monomers chosen from piperylenes, cyclic pentadienes, aromatics, limonenes, pinenes, amylenes, and combinations thereof. The method comprises melt processing a mixture to form the elastomeric composition in the shape of an article, wherein the mixture comprises elastomer, Si-HPM, silica, bifunctional organosilane crosslinking agent; and curing the elastomeric composition to form the article. Also disclosed are a silylated hydrocarbon polymer modifier coupled with a bifunctional organosilane crosslinking agent, and a silica-coupled hydrocarbon polymer modifier coupled to the silica via the bifunctional organosilane crosslinking agent.

Abstract: Cross-linked tetrapolymers made up of different diallyl zwitterionic diallyl quaternary ammonium salt monomers, with one of them functioning as a cross-linking monomer. The cross-linked terpolymers include a repeating unit with multiple ligand centers that different metal ions can bind to. The cross-linked tetrapolymers are cationic, zwitterionic and anionic, and can be in either an acidic form or a basic form. A method of removing metal ions from an aqueous solution with these cross-linked tetrapolymers is also described.

Abstract: Unsaturated compounds of the general formula (I) where R1, R2, R3 are the same or different and are each independently H, CH3, R4 is a linear or branched C1-C30-alkylene, R5, R6 are the same or different and are each independently, H, C1-C20-alkyl, C3-C15-cycloalkyl, aryl, —CH2—O—C1-C20-alkyl, —CH2—O—C2-C20-alkenyl, where R5 and R6 may together form a C3-C6-alkylene, R7, is the same or different and is independently, H, C1-C4-alkyl, R8 is C1-C22-alkyl, C2-C22-alkenyl, and n is an integer from 2 to 200. Mixtures and polymers comprising compounds of the general formula (I). A method for preparing polymers wherein a free-radical polymerization of monomers comprising unsaturated compounds of the general formula (I) is carried out. A process for preparing polymers comprising polymer-analogous reactions.

Abstract: A polymer having a contact angle with water that is greater than or equal to 90° and a contact angle with 1,3-propane diol that is less than 90°. A pervaporation membrane comprising the polymer and a process for purifying a fermentation broth using a pervaporation membrane comprising the polymer is also described.

Abstract: The present embodiments provide a system and method for separation within a polymer production process. Specifically, a flashline heater configured according to present embodiments may provide more time than is required for complete vaporization of liquid hydrocarbons that are not entrained within a polymer fluff produced within a polymerization reactor. Such extra time may allow for liquid hydrocarbons that are entrained within the polymer fluff to be vaporized.

Abstract: The present invention provides a catalyst component for olefin polymerization and a preparation method thereof, and a catalyst for olefin polymerization and an application thereof. The catalyst component for olefin polymerization comprises reaction products of the following components: (1) a solid component; (2) at least one titanium compound; and (3) at least two internal electron donors, wherein the solid component comprises a magnesium compound represented by formula (1) and an epoxide represented by formula (2), wherein R1 is a C1-C12 linear or branched alkyl; R2 and R3 are identical or different, and are independently hydrogen or unsubstituted or halogen-substituted C1-C5 linear or branched alkyl; X is halogen; m is in a range of from 0.1 to 1.9, n is in a range of from 0.1 to 1.9, and m+n=2.

Abstract: The invention provides a polymer system, including a first composition and a second composition. The first composition is different from the second composition. The first composition includes a first gelator, the first gelator including a plurality of acylhydrazine moieties. The second composition includes a second gelator, the second gelator including a plurality of formyl moieties. At least one of the first composition and the second composition includes a prepolymer. The invention further provides a method of using the polymer system to form a polymeric material via multiple stages to more effectively control the rheology of the components over a variety of timescales.

Abstract: A photocurable resin composition for three-dimensional printing which is visible-light curable is provided, comprising a photosensitive prepolymer in a range of 76.5 wt % to 96.8 wt %, a photoinitiator in a range of 0.01 wt % to 5 wt %, an auxiliary photoinitiator in a range of 0.01 wt % to 15 wt %, and a solvent in a range of 0.01 to 10 wt %. A three-dimensional printing system comprises: an accommodation unit, a lifting unit, a formation unit, and a control unit. The accommodation unit is for accommodating a printing material. The formation unit, which is connected to the lifting unit, can be driven by the lifting unit so as to move with respect to a light emission unit. The control unit, coupled to the lifting unit, controls motion of the lifting unit. The light emission unit may be a mobile electronic device, a display device, or a digital television.

Abstract: The present invention is directed to catalytic compositions and to curable compositions containing them. Catalytic compositions of the present invention typically comprise: (i) a reactive compound comprising at least one group selected from acid-functional groups and/or groups that may be converted to acid-functional groups; (ii) a metal compound; and (iii) a compound different from (i) and (ii) that catalyzes an addition reaction between an ethylenically unsaturated compound and a thiol. Curable compositions according to the present invention comprise: (a) a polyene, (b) a polythiol, and (c) the afore mentioned catalytic composition.